PT  - JOURNAL ARTICLE
AU  - Cristiano B.  Campanholo
AU  - Ajesh B.  Maharaj
AU  - Nadia Corp
AU  - Stacie Bell
AU  - Luisa Costa
AU  - Kurt  de Vlam
AU  - Nicola J.  Gullick
AU  - Majed Khraishi
AU  - Mitsumasa Kishimoto
AU  - Natalia Palmou-Fontana
AU  - Soumya Reddy
AU  - Raffaele Scarpa
AU  - Luis Vega
AU  - Gleison Vieira  Duarte
AU  - Devy Zisman
AU  - Danielle A.  van der Windt
AU  - Mehmet T.  Duruoz
AU  - Alexis Ogdie
TI  - Management of Psoriatic Arthritis in Patients With Comorbidities: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
AID  - 10.3899/jrheum.220310
DP  - 2022 Nov 01
TA  - The Journal of Rheumatology
PG  - jrheum.220310
4099  - http://www.jrheum.org/content/early/2022/10/26/jrheum.220310.short
4100  - http://www.jrheum.org/content/early/2022/10/26/jrheum.220310.full
AB  - Objective The 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations provide an evidence-based guide for selecting therapy based on the individual's disease features. Beyond the disease features and associated conditions (eg, uveitis and inflammatory bowel disease), comorbidities play an important role in selecting therapy for an individual patient. Methods We performed a systematic literature review. We examined the available evidence to inform treatment selection based on the presence or absence of comorbidities in psoriatic arthritis (PsA). Results Common comorbidities in PsA that may affect treatment selection include presence of baseline cardiovascular disease (CVD) or high risk for CVD, obesity and metabolic syndrome, liver disease, mood disorders, including depression in particular, chronic infections, malignancies, osteoporosis, and fibromyalgia and/or central sensitization. Conclusion Comorbidities may influence both the effectiveness of a given therapy but also the potential for adverse events. It is important to assess for the presence of comorbidities prior to therapy selection.